anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neuropharmacological intervention with monoaminergic drugs in healthy subjects can either augment, have no effect, or hamper brain function. We hypothesize that these population differences might be related to differences (high vs. low) in monoaminergic synaptic function which may be due to specific allelic variations in monoamine system genes (e.g., various synaptic proteins, synthetic enzymes, etc.). We wish to examine the effect of dextroamphetamine, a non-specific monoaminergic drug, on cognitive efficiency while subjects perform a variety of tasks including memory challenges with increasing cognitive load and varying rewards, selective attention and emotional processing. Further, in collaboration with other NIMH neuroimaging protocols, we wish to examine the neurophysiological correlates of these effects. We believe this protocol will provide a matrix for many investigations to elucidate important neurophysiological mechanisms that underlie normal cognition and cognitive efficiency. It is anticipated that these studies would be of potential 'pharmacogenetic' importance with regard to individual differences in the metabolism of monoaminergic drugs in normal health, aging and in disease.
PROBLEM TO BE SOLVED: To provide a food for preventing diabetes by inhibiting α-amylase.SOLUTION: Hot water extraction is performed by contacting 2 g of tea leaves of mid-mother plant Agr. No. 6 of camellia taliensis hybrid with 100 mL of hot water at 100°C for 7 minutes. The hot water extract is dried to obtain a dried product which contains 1,2-di-O-galloyl-4,6-HHDP-b-d-glucopyranose (CT-1) at high concentration. The CT-1 prevents diabetes through prevention of after-meal hyperglycemia by inhibiting α-amylase. The CT-1 is contained in camellia sasanqua, camellia taliensis, camellia irrawadiensis, camellia sinensis, and tea-walnut as a hybrid thereof. The CT-1 is added to and dissolved in a commercially available green tea (Yabukita tea), so as to produce a tea beverage containing the CT-1 at high concentration. The CT-1 may be added to a food in a liquid form, a paste form, a solid form, or a suspended form, in a similar way.
In this study, 259 participants were recruited from November 2019 to March 2022. All participants originated from a genetic counseling clinic of a cancer center in Shanghai, China. 259 participants were contact, and among them, 158 participants finally agreed to participate and completed the survey.
Subjects will be exposed to clean air for 3 hours at the first exposure visit and 0.2ppm ozone for 3 hours at the second exposure visit. The visits will be at least 2 weeks apart.
This article explores the experiences of the use of the Regional Health and Social Care Hospital Passport (Regional Hospital Passport) in Northern Ireland from the perspectives of adults with intellectual disabilities, family carers and health professionals. From semi-structured interviews three themes emerged: usefulness; facilitators; and barriers to the use of the Regional Hospital Passport. There were clear benefits of the Hospital Passport when used across hospital services and clinical practice settings such as dental and General Practices. There was participant agreement that communication and the person-centred care experiences were enhanced. Findings suggest that providers of health and social care services need to take greater responsibility and accountability for ensuring Regional Hospital Passports are promoted and used across all settings. There is a requirement to develop the wider use and uptake of hospital passports to support adults with intellectual disabilities, with potential for use with other patient groups.
Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
<P>PROBLEM TO BE SOLVED: To provide a bleaching agent and a bleaching cosmetic containing citric acid or extracts from plants such as Schizandra chinensis Baill., Schizandura repanda (Sieb. et Zucc.) Radlk., Kadsura japonica Dunal. and Kadsura japonica Dunal. or Kadsura longipendunculata Finet. et Gagnepen or Kadsura peltigera Rehd. containing citric acid as essential component.  <P>SOLUTION: The bleaching agent and bleaching cosmetic have excellent bleaching effects and effectively inhibit and ameliorate pigmentation of skin such as dermal stains, ephelides, dullness or skin blackening caused by ultraviolet exposure. The bleaching agent and bleaching cosmetic are extremely highly safe for even human bodies and usable over a wide range in the fields of medicines, quasi-drugs and cosmetics.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
OBJECTIVE: To understand the association between chronic inflammation, cellular senescence, and immunological infiltration in endometriosis.
METHODS: Datasets from GEO comprising 108 endometriosis and 97 healthy human samples and the human endometrial stromal cell. Differentially expressed genes were identified using Limma and WGCNA. Inflammatory response-related subtypes were constructed using consensus clustering analysis. The CIBERSORT algorithm and correlation analyses assessed immune cell infiltration. LASSO, SVM-RFE, and RF identified diagnostic genes. Functional enrichment analysis and multifactor regulatory networks established functional effects. Nomograms, internal and external validations, and in vitro experiments validated the diagnostic genes.
RESULTS: Inflammatory response subtypes were highly correlated with the immune activities of B and NK cells. Sixteen genes were associated with inflammatory response and cellular senescence and six diagnostic genes (NLK, RAD51, TIMELESS, TBX3, MET, and BTG3) were identified. The six diagnostic gene models had an area under the curve of 0.828 and their expression was significantly downregulated in endometriosis samples. Low expression of NLK and BTG3 promoted the proliferation, migration, and invasion of endometriotic cells.
CONCLUSIONS: Inflammatory response subtypes were successfully constructed for endometriosis. Six diagnostic genes related to inflammatory response and cellular senescence were identified and validated. Our study provides novel insights for inflammatory response in endometriosis and markers for endometriosis diagnosis and treatment.
The method involves recording a multiplet of specific information of radiological examination of a subject in an information system. Data is selected in multiplet of information, and coded based on predetermined coding for obtaining a specific graphic coded mark of a radiographic exposure. A radiographic film is tattooed during its pulling by a hard copy device by the specific coded graphic mark. The data of the mark coded is read and decoded by an optical reading system. The concerned radiological exposure is identified. Independent claims are also included for the following: (1) a computer program product comprising a set of instructions for managing data relative to a radiographic film obtained by pulling from a digital radiographic image resulting from an exposure of a subject to ionizing radiation from a source (2) a storage medium comprising a set of instructions for managing data relative to a radiographic film obtained by pulling from a digital radiographic image resulting from exposure of the subject to ionizing radiation from a source (3) a device for pulling film from a digital radiographic image for implementation of a method for managing data relative to a radiographic film obtained by pulling from a digital radiographic image resulting from an exposure of a subject to ionizing radiation from a source.
This solution is for intravenous use only.

Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

The presence of calcium ions in this solution should be considered when phosphate is present in additive solutions, in order to avoid precipitation.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

Ceftriaxone must not be administered simultaneously with calcium-containing intravenous solutions such as Lactated Ringer’s Injection USP via a Y-site. However, in patients other than neonates, ceftriaxone and Lactated Ringer’s Injection USP may be administered sequentially if the infusion lines are thoroughly flushed between infusions with a compatible fluid [see Contraindications, Warnings, Drug Interactions, Pediatric Use].

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
The placebo group, "EPID NS", will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses).
Donepezil hydrochloride is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically as (±)-2, 3-dihydro-5, 6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride. Donepezil hydrochloride is commonly referred to in the pharmacological literature as E2020. It has a molecular formula of C24H29NO3HCl and a molecular weight of 415.96. Donepezil hydrochloride, USP is a white to off-white crystalline powder. It is freely soluble in chloroform, soluble in water and in glacial acetic acid, slightly soluble in ethanol and in acetonitrile and practically insoluble in ethyl acetate and in n-hexane.

Each donepezil hydrochloride orally disintegrating tablet, USP intended for oral administration contains 5 mg or 10 mg of donepezil hydrochloride. In addition, each tablet contains the following inactive ingredients: ammonium glycyrrhizate, colloidal silicon dioxide, crospovidone, flavor peppermint, flavor strawberry, magnesium stearate, mannitol and sucralose.
The invention discloses an application of coumarin derivatives in preparing a medicament for treating inflammatory enteritis. Cell and animal pharmacodynamic experiments show that the coumarin derivative 6-bromo-7-hydroxy-8-nitro-3- (1H-tetrazol-5-yl) -2H-benzopyran-2-one (CMD174716) has remarkable wound healing promotion capability on rat small intestine crypt epithelial cell scratches, and has a good therapeutic effect on a DSS-induced mouse inflammatory enteritis model. Thus, CMD174716 can be used for the preparation of a medicament for the treatment of inflammatory bowel disease. The CMD174716 for preparing the medicine for treating inflammatory enteritis is a pharmaceutical composition prepared by using CMD174716 as an active ingredient and a conventional pharmaceutical carrier. The pharmaceutical composition can be tablets, granules, capsules, sustained-release tablets, dripping pills, injections, powder injections or aerosols and the like. The invention provides a new medicine for treating inflammatory enteritis, and has better clinical application prospect.
Recent advances in genetic testing have allowed for pathogenic mutation identification in family members of affected individuals prior to onset of symptoms. While the presence of mutation and the corresponding TTR kinetic stability have been directly linked to disease development, the molecular drivers of tissue specific degeneration have not been defined. We hypothesize that soluble misfolded TTR oligomer species may be circulating within the blood of these patients possibly years prior to amyloid deposition and could serve as an early biomarker and/or driver for disease development. In this line, The Scripps Research Institute has developed a peptide-based probe that specifically labels and integrates into misfolded TTR oligomers allowing the relative circulating concentration in the bloodstream to be determined. Longitudinal monitoring of untreated, asymptomatic TTR amyloid genetic carriers utilizing the Scripps probe is likely to provide novel insight into early disease progression. We also plan to utilize the Scripps probe to monitor disease progression in TTR amyloid genetic carriers currently undergoing treatment by observing how treatments affect the circulating misfolded TTR oligomers. Through enhanced understanding of early disease progression and treatment efficacy, our hope is to limit amyloid accumulation in cardiac and nerve tissue and delay the development of the invariably fatal TTR amyloid cardiomyopathy/neuropathy.
Due to dietary westernization and overweight, the number of knee joint degeneration is increasing year by year. Degeneration of knee arthritis can lead to pain and not exercise, and thus other chronic diseases. When the weight loss exceeds 5.1%, the function of the knee joint can be significantly improved and low heat weight loss (1200 kcal / day) and very low heat weight loss (less than 800 kcal / day) both weight loss The results are equally good .Many studies have shown that early and mid-interventional resistance exercise can improve muscle weakness, pain and stiffness in patients with degenerative knee arthritis, and elastic resistance exercise can effectively improve lower limb function and increase physical activity in patients with knee arthritis However, there has been no research on the effects of diet control and resistance exercise training on pain relief, body composition, lower limb function and quality of life in obese knee degenerative arthritis. The purpose of this study was to explore the degenerative knee degeneration. The effect of arthritis on the composition of the body after a balanced diet calorie control and home-based low-intensity elastic resistance movement; and whether persistent exercise habits and diet control can relieve pain, strengthen muscle strength, improve quality of life and other risks The effect of factor decline. Expected to combine the diet control and home group exercise to improve the quality of life of patients with degenerative knee arthritis.
BACKGROUND: Aortic valve stenosis (AVS) is currently the most common heart valve disease. The results of observational studies on the incidence of AVS in the renal dysfunction population are contradictory due to the short follow-up period and different diagnostic criteria, etc. This study aimed to explore the causal relationship between kidney function and AVS using Mendelian randomization (MR) analysis.
METHODS: We acquired summary statistics of estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD) from the CKDGen Consortium and a study on AVS from the FinnGen biobank. Univariate and multivariable MR analyses were conducted to evaluate the causal associations. The MR-Egger intercept and MR-PRESSO Global test were applied to assess the pleiotropic effects. The heterogeneity of MR results was tested by Cochran's Q statistic. Moreover, the Bonferroni and FDR corrections were performed for multiple tests.
RESULTS: Genetically predicted decreased eGFR may be associated with a raised risk of AVS (OR = 0.045, p = 1.317e-04 by IVW; OR = 0.002, p = 0.004 by MR-Egger, OR = 0.091, p = 0.057 by WM). The causal association still established after multiple comparisons. Quality control analyses indicated the absence of heterogeneity and pleiotropy in our MR research. In addition, the causality of eGFR and AVS remained significant in multivariable MR analysis after adjusting BMI, hypertension, T2DM, LDL-C, and smoking.
CONCLUSION: Our MR study discovered that reduced eGFR may be a causative risk factor for AVS. In addition, the evidence did not support a significant causal association of AVS on kidney function.
The patients pass the spontaneous breathing trial and are successful extubated without reintubation within 72 hours. .
PURPOSE:To obtain the subject preparation capable of continuously releasing an active substance when administered to a mucosa in the form of suppository, film preparation, etc., by compounding a hydrophilic polymeric compound, a hydrophilic low-molecular compound, a water-soluble physiologically active protein and a proteinase inhibitor. CONSTITUTION:The objective preparation is composed of 50-150pts.wt. of a hydrophilic polymeric compound (e.g. carboxyvinyl polymer or polyvinyl acetate), 1-30pts.wt. of a hydrophilic low-molecular compound (e.g. oligosaccharide or sucrose), 0.1-20pts.wt. of a water-soluble physiologically active protein (e.g. insulin or angiotensin), 0.01-1pt.wt. of a proteinase inhibitor (e.g. gabexate mesylate or alpha1-antitrypsin) and 0-20pts.wt. of an absorption assistant. The preparation has high releasability of active protein to enable the continuous application of the drug action to the whole body by the application to the mucosa and has extremely high absorbability and bioavailability of the active protein. There is no problem e.g. induration of the administered part caused by injection.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to restorative medicine, balneology and physiotherapy, pediatrics, nephrology and can be used for rehabilitation of children with secondary chronic pyelonephritis, including obstructive variant of secondary chronic pyelonephritis with underlying vesicoureteral reflux. Amplipulse pelotherapy of kidney projection area is performed by transverse technique at mud temperature 38–39 °C. Forked anode is placed in the area of the renal projection, and the cathode – in the projection of the urinary bladder and lower one-third of the ureters. Using rectified mode, 3 and 4 type of operation, duration of exposure to each type of work for 4 or 5 minutes. Modulation frequency of 80 Hz and a modulation depth of 50 % are used. Force of current is brought to sensation of moderate painless vibration. Procedure is performed for 10 or 12 or 15 minutes depending on the patient's age. Therapeutic course includes 10 procedures every other day in turn with balneal procedures. Balneal procedures are prescribed in the form of sodium chloride baths with mineralization of 10–20 g/l and temperature of 36–37 °C, course of 10 procedures every second day. Duration of the procedure makes either 8, 10 or 12 minutes depending on the patient's age.EFFECT: method provides eliminating the immune imbalance, reducing the inflammatory process in the kidneys, recovering the urodynamics of the upper and lower urinary tracts due to the combined effect of peloid therapy with sinusoidal modulated currents and sodium chloride baths.1 cl, 2 tbl, 2 ex
OBJECTIVES: Spinal cord stimulation (SCS) is a treatment option for patients with refractory angina pectoris (RAP) which was first used in 1987 and led to a reduction in the number of angina pectoris episodes, less consumption of short-acting nitrates, and an improvement in the quality of life. The conventional mode of stimulation leads to paresthesia felt at the target area. In recent years novel modes of stimulation have been developed that are paresthesia free, such as "burst," "high-density (HD)," or "high-frequency/10 kHz" stimulation. To date, these new modes of stimulation have not been used in patients with RAP and a spinal cord stimulator. This retrospective, single-center, observational study gives a description of the experience of using HD stimulation in selected patients with RAP being treated with SCS.
MATERIALS AND METHODS: All patients with RAP who received a spinal cord stimulator as treatment at our center from September 2009 to February 2021 were screened. Patients were eligible for inclusion into this retrospective, observational study if 1) patients had used HD stimulation, or 2) were currently using HD stimulation.
RESULTS: Fifty-three patients out of a total of 157 patients who had a spinal cord stimulator due to RAP use or have used HD stimulation. In most patients (79.2%), the reason for switching from conventional to HD stimulation was due to progression of symptoms under conventional stimulation. The average duration of conventional stimulation use prior to switching to HD stimulation was 40.3 (± 29.6) months. In total, 26 patients (of 53 patients; 49.1%) were using HD stimulation at the end of the follow-up period or until lost to follow-up, and two patients used both forms of stimulation interchangeably. Five patients (9.4%) had stopped using SCS, and 20 patients (37.7%) switched back to conventional stimulation due to a variety of reasons.
CONCLUSIONS: This retrospective study shows that the use of HD stimulation in patients with RAP being treated with SCS could be an alternative option for conventional stimulation. Due to the nature of this study, additional research is essential to confirm these initial findings.
BACKGROUNDDisease due to dengue viruses is a growing global health threat, causing 100-400 million cases annually. An ideal dengue vaccine should demonstrate durable protection against all 4 serotypes in phase III efficacy trials, however the lack of circulating serotypes may lead to incomplete efficacy data. Controlled human infection models help downselect vaccine candidates and supply critical data to supplement efficacy trials. We evaluated the efficacy of a leading live-attenuated tetravalent dengue vaccine candidate, TV005, against infection with a newly established dengue serotype 3 or an established serotype 2 challenge virus.METHODSTwo randomized, controlled clinical trials were performed. In study 1, a total of 42 participants received TV005 or placebo (n = 21 each), and 6 months later, all were challenged with dengue 2 virus (rDEN2Δ30) at a dose of 103 PFU. In study 2, a total of 23 participants received TV005 and 20 received placebo, and 6 months later, all were challenged with 104 PFU dengue 3 virus (rDEN3Δ30). The study participants were closely monitored for safety, viremia, and immunologic responses. Infection, measured by post-challenge viremia, and the occurrence of rash and neutropenia were the primary endpoints. Secondary endpoints included safety, immunologic, and virologic profiles following vaccination with TV005 and subsequent challenge with the rDEN2Δ30 or rDEN3Δ30 strain.RESULTSTV005 was well tolerated and protected all vaccinated volunteers from viremia with DENV2 or DENV3 (none infected in either group). Placebo recipients had post-challenge viremia (100% in study 1, 85% in study 2), and all experienced rash following challenge with either serotype.CONCLUSIONSTV005 is a leading tetravalent dengue vaccine candidate that fully protected against infection with DENV2 and DENV3 in an established controlled human infection model.TRIAL REGISTRATIONClinicalTrials.gov NCT02317900 and NCT02873260.FUNDINGIntramural Research Program, NIH (contract HHSN272200900010C).